A Phase 1 interventional study of Aripiprazole, oral formulation and Olanzapine, oral formulation in Psychotic Disorders, Schizophrenia and Bipolar Disorder, sponsored by Janssen Research & Development, LLC. Completed at 24 sites in 7 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2015-10-29.
Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing paliperidone in Psychotic Disorders — 1 open to participants now, 1 under way, none of them phase 3. paliperidone · Psychotic Disorders.
Among the 22 studies testing paliperidone in Psychotic Disorders, this one is the 8th largest by enrollment, is the only one that started in 2014, is one of 6 in phase 1, and was the 13th registered.
1,589 studies on the registry are indexed under Psychotic Disorders; 281 are open to participants now.
Browse Psychotic Disorders studies →1 of the 22 studies testing paliperidone in Psychotic Disorders is open now. Recruiting first, the newest first:
Consorcio Centro de Investigación Biomédica en Red (CIBER)
Ages 15–40
paliperidone: first FDA approval 2006 (INVEGA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 204 Psychotic Disorders studies recruiting now, 53 (26%) set no upper age limit and 142 (70%) stop at 75 or younger; 50 take children under 18; 41 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 2 · Phase 3 7 · Phase 4 8
First in 2003; this study’s year is marked. 1 started in 2014.
This study's enrollment of 305 is above the median of 65 across 1,322 interventional studies indexed under Psychotic Disorders.
Median enrollment 189 across the 22 interventional studies. Of the 20 that completed or were terminated, 7 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 22 have an industry lead sponsor. The 10 most frequent:
This study is registered under Janssen Research & Development, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.
Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.
58 studies in Psychotic Disorders by Johnson & Johnson: 1 open now, 1 under way, none of them phase 3. Of 57 finished, 12 (21%) have results posted.
Among the 58 studies in Psychotic Disorders by Johnson & Johnson, this one is the 21st largest by enrollment of the 49 interventional ones that give a count, is the only one that started in 2014, is one of 8 in phase 1, and was the 54th registered.
Johnson & Johnson’s Psychotic Disorders studies by the year they started, since 1996.
None of the studies under way reaches primary completion within a year.
Among the 22 studies testing paliperidone in Psychotic Disorders, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Johnson & Johnson’s 58 in Psychotic Disorders:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to gather information about the steady-state plasma concentrations of aripiprazole, olanzapine, quetiapine and their relevant metabolites, at various dose levels and at different time points after dosing. In addition, comparison of capillary drug concentrations vs. venous drug concentrations will be performed for aripiprazole, olanzapine, paliperidone, quetiapine, risperidone and their relevant metabolites.
This is an open-label (physicians and participants know the identity of the assigned treatment), parallel-group, multiple-dose, multicenter study to assess pharmacokinetics (what the body does to the medication) of five antipsychotics (APS) drugs: aripiprazole, olanzapine, paliperidone, quetiapine and risperidone in psychiatric participants who are receiving stable doses of these drugs for the treatment of their disease.
Pharmacokinetics data will be generated from venous and fingerstick-based capillary plasma concentrations of the drugs and their metabolites. The total number of enrolled participants in this study will be at least 265. Seventy-five participants will be enrolled for the aripiprazole, olanzapine and quetiapine cohorts (groups) each, and 20 participants will be enrolled for the paliperidone and risperidone cohorts each. In aripiprazole, olanzapine and quetiapine cohorts there will be two subgroups. Subgroup one, 20 participants for fingerstick capillary + venous blood sampling and subgroup two, 55 participants for only venous sampling. Paliperidone and risperidone cohorts will be subjected only to capillary + venous blood sampling.
The study will consist of a screening phase (within 21 days before Day 1) followed by a 3-day observation phase (Day 1 to Day 3). Participants will be admitted to the study center in the evening of Day -1 and will remain in the study center until discharged on Day 3 after completion of the last study-related procedure. During the observation phase, the administration of the prior antipsychotic medication will continue at a participant's usual dose and dosing schedule, under direct observation of the study staff. There will be no modification of the participant's medication during the study. Safety will be evaluated throughout the study and a mandatory pharmacogenomic blood sample will be collected for analysis of genes that may influence exposure of the APS studied.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Administration of oral formulation will continue at a participant's usual dose and dosing schedule.
Drug: Aripiprazole, oral formulation
Administration of oral formulation will continue at a participant's usual dose and dosing schedule.
Drug: Olanzapine, oral formulation
Administration of prolonged-release (extended-release) tablets or long-acting injectables (LAI) will continue at a participant's usual dose and dosing schedule.
Drug: Paliperidone, oral formulation · Drug: Paliperidone, LAI
Administration of oral formulation will continue at a participant's usual dose and dosing schedule.
Drug: Quetiapine, oral formulation
Administration of oral formulation or LAI will continue at a participant's usual dose and dosing schedule.
Drug: Risperidone, oral formulation · Drug: Risperidone, LAI
Aripiprazole tablets will be administered orally (by mouth), at no dose restriction, as per the locally approved label indications.
Olanzapine tablets will be administered orally, at no dose restriction as per the locally approved label indications.
Paliperidone prolonged-release/extended-release (XR) formulation tablets will be administered orally, at no dose restriction, as per the locally approved label indications.
Also known as: INVEGA®
Paliperidone long-acting injectable (LAI) i.e., paliperidone palmitate injections, will be administered per the locally approved label indications.
Also known as: INVEGA®
Quetiapine immediate-release (IR) formulation or extended-release (XR) formulation tablets will be administered orally, at no dose restriction, as per the locally approved label indications.
Risperidone tablets will be administered orally, at no dose restriction, as per the locally approved label indications.
Also known as: RISPERDAL®
Risperidone LAI injections will be administered will be administered per the locally approved label indications.
Also known as: RISPERDAL®
Aripiprazole concentration in venous and capillary plasma
Venous blood samples will be collected at 8 scheduled time points after dosing and compared to fingerstick-based capillary blood samples collected at 6 scheduled time points after dosing.
Time frame: 14 time points over 3 days postdose
Paliperidone concentration in venous and capillary plasma
Time frame: 14 time points over 3 days postdose
Olanzapine concentration in venous and capillary plasma
Time frame: 14 time points over 3 days postdose
Quetiapine concentration in venous and capillary plasma
Time frame: 14 time points over 3 days postdose
Risperidone concentration in venous and capillary plasma
Time frame: 14 time points over 3 days postdose
Number of participants with an adverse event as a measure of safety
Time frame: Participants will be followed for the duration of hospital stay, an expected average of 3 days
The record gives a start of Feb 2014, a primary completion of Oct 2014 and a completion of Dec 2014. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Paliperidone · Risperidone
Janssen Research & Development, LLC →